drugset / Trial / NCT00036426

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

NCT00036426

Phase 2 Unknown 22 enrolled Favrille
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine if an idiotype vaccine, made from a patient's lymphoma that has returned after chemotherapy and/or rituximab, would be able to shrink their tumor.

Timeline

Start
2001-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject FavId™ Vaccine